Neil Averitt commentary: New ideas wanted for assessing pharma deals
Both federal antitrust agencies are looking for new ideas to deepen their analysis of pharmaceutical mergers, and now they have the workshop to prove it....
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login
to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information:
FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch